Coronary Heart Disease, Periodontal Disease
Conditions
Keywords
Non-surgical periodontal therapy, Coronary heart disease (CHD), periodontal Disease, hsCRP, Fibrinogen, WBCs
Brief summary
Currently the research issue in establishing the role of periodontal disease (PD) in coronary heart disease (CHD) risk is to define the pathways that lead to cause-effect relationship between PD and CHD. There is no consensus on definition of a periodontal disease case or the threshold level that may give clear indication for this relationship. Periodontal therapy has been used in different studies with the hope that a change in periodontal disease status may modify the factors associated with CHD risk. Many of these studies, on role of periodontal therapy in the reduction of CHD associated risk-factors, were based on small study samples, and very few studies were randomized controlled trials. So a need for large prospective studies is warranted in literature.----------- A single-blind parallel-arm randomized controlled clinical trial was designed to observe the influence of periodontal treatment on serum inflammatory mediators of hsC-reactive protein, white blood cells and fibrinogen in CHD patients. Hypothesis: Periodontal therapy in CHD patients, by reducing periodontal inflammation, may decrease the host systemic inflammatory burden associated with atherogenic processes.
Interventions
Scaling, Root Planing and oral hygiene instruction
Scaling, root planning and oral hygiene instructions
Sponsors
Study design
Eligibility
Inclusion criteria
A. General/Medical 1. Any race/ethnic group 2. Aged \> 30 years 3. Male or female 4. CHD case (CHD angiographically confirmed) 5. CHD diagnosed \> 3 months prior to entry into study. 6. No acute or chronic systemic conditions (see
Exclusion criteria
below) 7. No medications/medication history that can interfere with the study (see
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| high-sensitivity C-Reactive Protein (hsCRP) | 1-3 months |
Secondary
| Measure | Time frame |
|---|---|
| Fibrinogen | 1-3 months |
| White Blood Cells | 1-3 months |
Countries
Pakistan